A B S T R A C T The effects of clofibrate administration were studied in rats made hyperlipidemic by the feeding of diets high in sucrose. Within 12 hr of administration of clofibrate, there was a marked decrease in the concentration of serum high density lipoproteins but no change in the concentrations of the low and very low density lipoproteins. Between 2-4 days of treatment, the concentration of the very low density lipoproteins decreased whereas that of the low density lipoproteins was unchanged. In addition, the composition of the very low density lipoproteins was altered by clofibrate administration with a decrease in triglyceride and an increase in phospholipid content.
INTRODUCTION
Clofibrate is widely used in the treatment of patients with hyperlipoproteinemia, but its mechanism of action is as yet not known (1 ) . Although studies have suggested that its primary role is that of an inhibitor of cholesterol biosynthesis (2) , other studies (3, 4) have shown that in rats, clofibrate also inhibits the transport Dr. Paul S. Roheim is a Career Scientist of the Health Research Council of New York City.
Received for publication 18 October 1971 and in revised form 27 January 1972. of triglyceride from the liver into the plasma. Gould, Swyryd, Avoy, and Coon (5) The semipurified high sucrose diet was obtained from General Biochemicals Div., Chagrin Falls, Ohio, and contained 20%. vitamin-free casein, 60%o sucrose, 4% corn oil, 1% vitamin mixture (Wooley and Sebrell [7] ), 4% salt mixture (USP XIV), and 10% cellulose. The treated rats received the same diet to which 0.25% clofibrate (w/w) was added. Rats received the diet without clofibrate for 7-14 days, and thereafter received the diet containing clofibrate for periods of time varying from 12 hr to 8 days. The experiments were carried out on a schedule in which all animals in an experimental group were killed at the same time (between 9 and 11 a.m.). The rats were given food and water ad lib. throughout the experiment. They were weighed three times a week and animals losing weight were excluded from the study. Weight gain was similar in the clofibrate-treated and control animals.
Chemical methods. Serum lipids were extracted by the method of Folch, Lees, and Sloane Stanley (8) 100 g of body weight; 90 min later 60 uCi of leucine-3H/ 100 g of body weight was injected into the same animals; and 60 min after this the animals were killed. This was done in order to measure incorporation of labeled amino acids in the same rat at two different times, 60 and 150 min. These time intervals were chosen because the maximal specific activity of VLDL is reached between 30 and 50 min after administration of the precursor, whereas the maximal specific activity for LDL and HDL is reached between 60 and 150 min.' Each group consisted of six to nine rats, and the serum of each rat was measured.
In another series of experiments, turnover was measured by administering 15 1uCi of uniformly labeled amino acids-"C/100 g of body weight to control rats and to rats treated with clofibrate for 40 hr. Groups of six control and six treated rats were killed at 1, 2.5, 5, and 10 hr after the injection of the labeled amino acids. RESULTS Serum lipid concentration. The effect of clofibrate administration for various periods of time on serum triglyceride and cholesterol concentration is shown in Fig. 1 cantly lower than the control after 12 hr of treatment, and remained low thereafter. Lipoprotein concentration. We have defined VLDL as the lipoproteins separated by ultracentrifugation at d < 1.006 at 114,000 g for 20 hr. This fraction therefore contained chylomicrons in addition to VLDL. Since these rats were not fasted, it was necessary to determine the contribution of chylomicron protein to this fraction in sera from both clofibrate-treated and control rats. Fig. 2 . VLDL protein concentration did not change until after the 2nd day of treatment; by the 4th day it had decreased by 50% and remained low thereafter. The LDL protein showed no consistent change. HDL protein concentration decreased by 40% within 12 hr after clofibrate administration and progressively decreased thereafter.
Composition of serum lipoproteins. In addition to changes in the concentrations of the lipoproteins, certain changes in composition were also observed. 8 days of clofibrate administration resulted in a decrease of 50% in the serum concentration of triglyceride present in the VLDL fraction. VLDL protein decreased but to a lesser extent. Phospholipid was the least affected. As a result, the VLDL of the clofibrate-treated rats was relatively poor in triglyceride and rich in phospholipids (Table  II) . In the HDL fraction, protein and cholesterol concentrations decreased proportionately. However, the decrease in HDL phospholipid concentration was greater than in the other components. As a result, HDL of the clofibrate-treated rat (Table II) contained less phospholipids and slightly more protein.
Incorporation of labeled leucine into lipoproteins. The effect of the administration of clofibrate on incorporation of either L-leucine-'H or L-leucine-"C into the protein portions of the various lipoproteins was measured. Radioactivity in VLDL was determined 60 min after administration of the labeled precursor; radioactivity in LDL and HDL was determined 150 min after administration of the labeled leucine. Fig. 3 shows the total incorporation of labeled amino acid into the three lipoprotein fractions after clofibrate administration. Incorporation into VLDL was increased during the first 2 days of treatment but appeared to decrease by the 4th and 8th days of treatment. Incorporation of labeled leucine into HDL decreased appreciably within 12 hr and decreased further thereafter. The specific activity (Fig.  4) of VLDL increased after administration of clofibrate while the specific activity of HDL protein was unchanged. However, the time course of labeling was unchanged by the administration of clofibrate.
In order to obtain information as to the rate of turnover of VLDL at different times after the administration of clofibrate, we employed, the method described by Schimke, Ganschow, Doyle, and Arias (19) whereby two time points on a decay curve can be determined in the same protein in the same animal. In this technique one isotopic form of an amino acid (14C) is administered initially. After a specified time, the second isotopic form ('H) of the same amino acid is administered, and the animal killed shortly thereafter. If certain assumptions are met, the 'H counts represent an initial time point, and the 14C counts represent a subsequent point on higher in the clofibrate-treated animals during the first 4 days of clofibrate administration and elevated to a lesser extent on the 8th day. These data suggest that the administration of clofibrate increases the rate of turnover of VLDL. Turnover was also determined by measurement of the specific activity of VLDL after the pulsed administration of labeled amino acids. Animals that had been treated with clofibrate for 40 hr and untreated animals were studied. The rats treated with clofibrate were killed at 1, 2.5, 5, and 10 hr after the injection of the labeled amino acids. The specific activity of the VLDL protein in the clofibrate-treated rats was almost twice as high in the treated as the control rats at the peak specific activity, 1 hr after injection of the labeled amino acids (Fig. 6) . The specific activity of the VLDL of the treated rats decreased at a more rapid rate than did the specific activity of the VLDL in the control rats. 10 hr after the injection of labeled amino acid, the specific activity of VLDL protein was significantly lower in clofibrate-treated animals than in the control group. These results indicate increased turnover rate of the VLDL protein and are in agreement with results obtained by the double label technique of Schimke et al. (19) . As a control, the specific activity curve of albumin was also determined. The albumin reached maximal specific activity in 2k hr and the turnover-curve was identical in the treated and control groups. This finding suggests that no changes in amino acid pool size have occurred in rats given clofibrate.
DISCUSSION
Clofibrate is widely used in the treatment of patients with hyperlipidemia. Accordingly, it would appear that hyperlipidemic rats would constitute a more appropriate model for the study of the mode of action of this drug. Hyperlipidemia was produced by feeding a diet high in sucrose. This results in a marked increase in the concentration of VLDL in the serum, no change in LDL concentration, and a lesser but significant increase in HDL. The synthesis of both VLDL and HDL protein is increased (20) . The administration of clofibrate to sucrose-fed rats resulted in a fall in serum cholesterol concentration within 12 hr and a decrease in triglyceride concentration that did not occur until after 2 days of clofibrate administration. HDL protein concentration decreased concomitantly with the decrease in serum cholesterol. VLDL protein concentration decreased after 2-4 days of treatment. The decrease in the concentration of VLDL protein was not as great as that of triglyceride; therefore, in the treated rats, the VLDL has a reduced triglyceride content. Recently, it has been shown that during the removal of VLDL from plasma, intermediates with reduced triglyceride content appear (21, 22) . In the presence of an accelerated rate of removal of VLDL, the finding of increased amounts of such "remnants" (23) FIGURE 6 Specific activities of serum VLDL and serum albumin after administration of amino acids-o"C. confirmed in the study where turnover-rate of VLDL as measured by the double isotope procedure of Schimke et al. (19) was found to be increased. Turnover of VLDL was also measured by the determination of the specific activity at various time intervals after administration of labeled amino acid and was also found to be increased. Thus it appears that soon after the administration of clofibrate, both the rate of synthesis and the rate of removal of VLDL are increased. However, the increased rate of synthesis is not sustained, and when it decreases in the presence of the increased rate of removal, the concentration of VLDL in the plasma decreases.
Since serum triglyceride is a major constituent of VLDL, changes in triglyceride metabolism are in many instances indicative of changes in the metabolism of VLDL protein. A number of workers have suggested that the rate of removal of triglyceride from the serum plays a major role in determining its plasma level (25, 26) . Spritz (27) There are, however, studies suggesting that administration of clofibrate inhibits the release of triglyceride into the plasma (3, 4, 31, 32). Gould et al. (5) have found decreased incorporation of amino acids-1'C into mixed lipoproteins by liver slices obtained from rats treated with clofibrate for 5 days. However, since the lipoproteins were not separated, this could be due to the decreased synthesis of HDL. Lipoprotein synthesis was also measured in intact rats by injection of labeled amino acids. Incorporation into HDL and into a mixed LDL plus VLDL fraction was found to be decreased.
It should be emphasized that our studies were carried out with sucrose-fed hyperlipidemic rats (20) . The use of such animals could account for the differences between our findings and those of others (3, (31) (32) (33) . It is of interest that Kokatanur and Wu (34) have shown that the effect of clofibrate on acetate incorporation into lipids differs between rats fed diets containing dextrose and those fed diets in which starch was the source of carbohydrate.
Lipoproteins were separated at densities of 1.006, 1.063, and 1.21, respectively. It is recognized that under these conditions, the LDL fraction (d 1.006-1.063) contains traces of HDL. However, in earlier studies we have found that in the rat fed a normal diet most of LDL appears between densities 1.040 and 1.050 (35) . The density distribution of LDL of the sucrose-fed rat appeared to be similar to that of the rats fed normal diets. Since the purpose of these experiments was to measure the total amounts of these various lipoprotein fractions, it was essential that the entire fraction be isolated. Had we been primarily interested in obtaining lipoprotein fractions uncontaminated with other lipoproteins, a narrower density range would have been separated, but at the expense of total recovery of any fraction. Furthermore, these conditions favor the isolation of all the VLDL and HDL at which this study has been primarily directed.
The mechanism whereby clofibrate exerts its effect on lipoprotein metabolism is, as yet, unknown. It is of particular interest that its initial effect is on HDL synthesis and only subsequently on VLDL. Since rat HDL and VLDL contain subunit polypeptides which are immunologically related (36) (37) (38) , it is tempting to speculate that the primary effect of clofibrate is on these particular subunit proteins. Because of this heterogeneity of the subunit proteins of the HDL and VLDL, it is possible that changes in the rate of turnover of the total proteins in a given fraction would reflect marked changes in the turnover of only some of the subunit polypeptides. Studies of the rate of turnover of the various subunit polypeptides are presently in progress in this laboratory.
